Showing results (21-30 of 31) with videos related to
Sort By:
Pageof 4
Molecular Medicine (Cambridge, Mass.)|November 22, 2012
Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot studyLara Heij, Marieke Niesters, Maarten Swartjes, et al.Frontiers in Human Neuroscience|June 6, 2024
The feasibility and usability of a personal health record for patients with multiple sclerosis: a 2-year evaluation studyLiselot N van den Berg, Jiska J Aardoom, Léone E Kiveron, et al.Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|May 11, 2005
Association of small fiber neuropathy with cardiac sympathetic dysfunction in sarcoidosisElske Hoitsma, Carin G Faber, Marinus J P G van Kroonenburgh, et al.Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|April 9, 2016
Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis populationMirjam J G Van Manen, Monique Wapenaar, Bert Strookappe, et al.Disability and Rehabilitation|November 9, 2019
A Dutch validation study of the Multiple Sclerosis Work Difficulties Questionnaire in relapsing remitting multiple sclerosisElianne van Egmond, Dennis van Gorp, Cynthia Honan, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 13, 2023
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosisAlyssa A Toorop, Zoé L E van Kempen, Maurice Steenhuis, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 20, 2019
Cognitive functioning as a predictor of employment status in relapsing-remitting multiple sclerosis: a 2-year longitudinal studyDennis A M van Gorp, Karin van der Hiele, Marco A P Heerings, et al.JAMA Neurology|December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical TrialEline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.Pageof 4